The role of single-nucleotide polymorphisms of the 8q24 chromosome region in patients with concomitant bladder and prostate cancer

References

• Gakis G, Stenzl A. Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol. 2013;31(5):1059–1064.
   PubMed Web of Science ®Google Scholar
• Gakis G, Stenzl A, Renninger M. Evolution of the concept of androgen-sensitive bladder cancer. Scand J Urol. 2013;47(3):173–178.
   PubMed Web of Science ®Google Scholar
• Chu LW, Meyer TE, Li Q, et al. Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1848–1854.
   PubMed Web of Science ®Google Scholar
• Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39(5):645–649.
   PubMed Web of Science ®Google Scholar
• Wu X, Ye Y, Kiemeney LA, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 2009;41(9):991–995.
   PubMed Web of Science ®Google Scholar
• Ishak MB, Giri VN. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1599–1610.
   PubMed Web of Science ®Google Scholar
• Fu YP, Kohaar I, Rothman N, et al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci USA. 2012;109(13):4974–4979.
   PubMed Web of Science ®Google Scholar
• Jain A, Lam A, Vivanco I, et al. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol. 2002;16(10):2323–2337.
   PubMedGoogle Scholar
• Joung JY, Lee YS, Park S, et al. Haplotype analysis of prostate stem cell antigen and association with prostate cancer risk. J Urol. 2011;185(6):2112–2118.
   PubMed Web of Science ®Google Scholar
• Wokolorczyk D, Gliniewicz B, Sikorski A, et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res. 2008;68(23):9982–9986.
   PubMed Web of Science ®Google Scholar
• Sobin LH, G MK, Wittekind C. TNM classification of malignant tumors. Vol. 7. Oxford: Wiley-Blackwell; 2002.
   Google Scholar
• Epstein JI, Allsbrook WC Jr., Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–1242.
   PubMed Web of Science ®Google Scholar
• , Altshuler DM, Gibbs RA, International HapMap C, et al. Integrating common and rare genetic variation in diverse human populations. Nature. 2010;467(7311):52–58.
   PubMed Web of Science ®Google Scholar
• Metzker ML. Sequencing technologies – the next generation. Nat Rev Genet. 2010;11(1):31–46.
   PubMed Web of Science ®Google Scholar
• Gakis G, Black PC, Bochner BH, et al. Systematic review on the fate of the remnant urothelium after radical cystectomy. Eur Urol. 2017;71(4):545–557.
   PubMed Web of Science ®Google Scholar
• Damiano R, Di Lorenzo G, Cantiello F, et al. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol. 2007;52(3):648–657.
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675.
   PubMed Web of Science ®Google Scholar
• Reiter RE, Sato I, Thomas G, et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosom Cancer. 2000;27(1):95–103.
   PubMed Web of Science ®Google Scholar
• Bahrenberg G, Brauers A, Joost HG, et al. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem Biophys Res Commun. 2000;275(3):783–788.
   PubMed Web of Science ®Google Scholar
• Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19(10):1288–1296.
   PubMed Web of Science ®Google Scholar
• Wang S, Tang J, Wang M, et al. Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population. Carcinogenesis. 2010;31(4):621–624.
   PubMed Web of Science ®Google Scholar
• , Sakamoto H, Yoshimura K, Saeki N, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet. 2008;40(6):730–740.
   PubMed Web of Science ®Google Scholar
• Saffran DC, Raitano AB, Hubert RS, et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA. 2001;98(5):2658–2663.
   PubMed Web of Science ®Google Scholar
• Gu Z, Yamashiro J, Kono E, et al. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res. 2005;65(20):9495–9500.
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother. 2006;55(12):1524–1533.
   PubMed Web of Science ®Google Scholar
• Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today. 1999;20(12):576–582.
   PubMedGoogle Scholar
• Marra E, Uva P, Viti V, et al. Growth delay of human bladder cancer cells by prostate stem cell antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer. 2010;10:129.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Stamova S, Bippes CC, et al. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate. 2011;71(9):998–1011.
   PubMed Web of Science ®Google Scholar
• Buhler P, Molnar E, Dopfer EP, et al. Target-dependent T-cell activation by coligation with a PSMA × CD3 diabody induces lysis of prostate cancer cells. J Immunother. 2009;32(6):565–573.
   PubMed Web of Science ®Google Scholar
• Kohaar I, Porter-Gill P, Lenz P, et al. Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer. J Natl Cancer Inst. 2013;105(1):69–73.
   PubMedGoogle Scholar